Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (170)	8/28/2002 12:41:33 AM
From: Vector1	Read Replies (1) \| Respond to of 447

Thanks Tuck. I have talked to a number of oncologists and MBs following the IRRESA failure. To a man they are both surprised, confused and disappointed. One who I respect greatly told me that {not an exact quote}" This is depressing. I didn't think it would have a dramatic effect in LC but it should have had some survival benefit." He went on to say that dosing can have a profound impact on a drugs efficacy in cancer. Thus Tarceva's greater potency could have an impact. V1